NRXBF
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of p… Read more
NRXBF (NRXBF) - Total Liabilities
Latest total liabilities as of September 2025: $1.19 Million USD
Based on the latest financial reports, NRXBF (NRXBF) has total liabilities worth $1.19 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NRXBF - Total Liabilities Trend (2021–2024)
This chart illustrates how NRXBF's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NRXBF Competitors by Total Liabilities
The table below lists competitors of NRXBF ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Touchstone Exploration Inc
PINK:PBEGF
|
USA | $164.80 Million |
|
Can Don Hydro Power JSC
VN:SJD
|
Vietnam | ₫425.61 Billion |
|
Hengs Technology Co., Ltd.
TWO:4582
|
Taiwan | NT$2.91 Billion |
|
Soosan Heavy I
KO:017550
|
Korea | ₩77.87 Billion |
|
Exel Industries
PA:EXE
|
France | €472.14 Million |
|
Power Root Bhd
KLSE:7237
|
Malaysia | RM222.80 Million |
|
Cineverse Corp.
NASDAQ:CNVS
|
USA | $30.83 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down NRXBF's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NRXBF's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NRXBF (2021–2024)
The table below shows the annual total liabilities of NRXBF from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $680.00K | -65.67% |
| 2023-12-31 | $1.98 Million | +183.81% |
| 2022-12-31 | $698.00K | -57.93% |
| 2021-12-31 | $1.66 Million | -- |